Literature DB >> 19659923

Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.

Tultul Nayyar1, Michael Bubser, Marcus C Ferguson, M Diana Neely, J Shawn Goodwin, Thomas J Montine, Ariel Y Deutch, Twum A Ansah.   

Abstract

Parkinson's Disease (PD) is marked by prominent motor symptoms that reflect striatal dopamine insufficiency. However, non-motor symptoms, including depression, are common in PD. It has been suggested that these changes reflect pathological involvement of non-dopaminergic systems. We examined regional changes in serotonin (5-HT) and norepinephrine (NE) systems in mice treated with two different 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment paradigms, at survival times of 3 or 16 weeks after the last MPTP injection. MPTP caused a decrease in striatal dopamine concentration, the magnitude of which depended on the treatment regimen and survival interval after MPTP treatment. There was significant involvement of other subcortical areas receiving a dopamine innervation, but no consistent changes in 5-HT or NE levels in subcortical sites. In contrast, we observed an enduring decrease in 5-HT and NE concentrations in both the somatosensory cortex and medial prefrontal cortex (PFC). Immunohistochemical studies also revealed a decrease in the density of PFC NE and 5-HT axons. The decrease in the cortical serotonergic innervation preferentially involved the thick beaded but not smooth fine 5-HT axons. Similar changes in the 5-HT innervation of post-mortem samples of the PFC from idiopathic PD cases were seen. Our findings point to a major loss of the 5-HT and NE innervations of the cortex in MPTP-induced parkinsonism, and suggest that loss of the beaded cortical 5-HT innervation is associated with a predisposition to the development of depression in PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659923      PMCID: PMC2765981          DOI: 10.1111/j.1460-9568.2009.06806.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  72 in total

Review 1.  Parkinson's disease: clinical features and diagnosis.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-04       Impact factor: 10.154

2.  Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson.

Authors:  H J Gundersen
Journal:  J Microsc       Date:  1986-07       Impact factor: 1.758

Review 3.  Depressive symptoms in Parkinson's disease.

Authors:  M R Lemke
Journal:  Eur J Neurol       Date:  2008-04       Impact factor: 6.089

4.  A controlled trial of antidepressants in patients with Parkinson disease and depression.

Authors:  M Menza; R D Dobkin; H Marin; M H Mark; M Gara; S Buyske; K Bienfait; A Dicke
Journal:  Neurology       Date:  2008-12-17       Impact factor: 9.910

Review 5.  Management of non-motor symptoms in advanced Parkinson disease.

Authors:  Daniel D Truong; Roongroj Bhidayasiri; Erik Wolters
Journal:  J Neurol Sci       Date:  2007-09-04       Impact factor: 3.181

6.  Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.

Authors:  David V Sheehan; Matthew S Keene; Michael Eaddy; Stan Krulewicz; John E Kraus; David J Carpenter
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Dystrophic serotonergic axons in neurodegenerative diseases.

Authors:  Efrain C Azmitia; Ralph Nixon
Journal:  Brain Res       Date:  2008-04-07       Impact factor: 3.252

8.  Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra.

Authors:  A Y Deutch; S Y Tam; R H Roth
Journal:  Brain Res       Date:  1985-04-29       Impact factor: 3.252

9.  Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

Authors:  Marta G Vucković; Ruth I Wood; Daniel P Holschneider; Avery Abernathy; Daniel M Togasaki; Alexandra Smith; Giselle M Petzinger; Michael W Jakowec
Journal:  Neurobiol Dis       Date:  2008-08-05       Impact factor: 5.996

10.  Sertraline in the treatment of depressive disorders in patients with Parkinson's disease.

Authors:  Silvia Marino; Edoardo Sessa; Giuseppe Di Lorenzo; Giuseppina Digangi; Antonella Alagna; Placido Bramanti; Paolo Di Bella
Journal:  Neurol Sci       Date:  2008-11-11       Impact factor: 3.307

View more
  15 in total

1.  Age- and duration-dependent effects of MPTP on cortical serotonin systems.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2011-09-21       Impact factor: 3.046

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

3.  5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch; Twum A Ansah
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

4.  MPTP-induced executive dysfunction is associated with altered prefrontal serotonergic function.

Authors:  Panchanan Maiti; Laura C Gregg; Michael P McDonald
Journal:  Behav Brain Res       Date:  2015-09-21       Impact factor: 3.332

Review 5.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 7.  New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease.

Authors:  Elena M Vazey; Gary Aston-Jones
Journal:  Brain Res       Date:  2013-01-18       Impact factor: 3.252

8.  MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain.

Authors:  Hanane Kadar; Gael Le Douaron; Majid Amar; Laurent Ferrié; Bruno Figadère; David Touboul; Alain Brunelle; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-12-18       Impact factor: 3.911

9.  Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Twum A Ansah
Journal:  Neurochem Int       Date:  2014-04-04       Impact factor: 3.921

10.  The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease.

Authors:  Elena M Vazey; Gary Aston-Jones
Journal:  Front Behav Neurosci       Date:  2012-07-25       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.